Tyra Biosciences, Inc. Share Price
TYRATyra Biosciences, Inc. Stock Performance
Open $33.95 | Prev. Close $33.09 | Circuit Range N/A |
Day Range $31.90 - $34.22 | Year Range $6.42 - $34.22 | Volume 40,107 |
Average Traded $33.32 |
Tyra Biosciences, Inc. Share Price Chart
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Tyra Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
25-Feb-26 | $34.02 | $34.51 | +2.03% |
24-Feb-26 | $34.01 | $33.83 | +1.49% |
23-Feb-26 | $32.63 | $33.33 | +5.49% |
20-Feb-26 | $30.85 | $31.59 | +0.94% |
19-Feb-26 | $29.17 | $31.30 | +6.43% |
18-Feb-26 | $29.02 | $29.41 | +0.91% |
17-Feb-26 | $28.01 | $29.14 | +4.15% |